Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK 297.30
+1.90 (0.64%)
Jul 20, 2026, 4:59 PM CET
Zealand Pharma Income Statement
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9,241 | 9,215 | 62.69 | 342.79 | 103.99 | 108.55 | |
Revenue Growth (YoY) | 16519.49% | 14598.86% | -81.71% | 229.65% | -4.20% | -43.47% |
Cost of Revenue | 0.41 | 0.82 | 7.87 | 19.17 | - | 10.97 |
Gross Profit | 9,240 | 9,214 | 54.82 | 323.61 | 103.99 | 97.58 |
Selling, General & Admin | 497.12 | 495.95 | 404.02 | 215.93 | 269.51 | 298.21 |
Research & Development | 1,783 | 1,605 | 919.87 | 684.9 | 614.04 | 581.51 |
Other Operating Expenses | 174.85 | 154.09 | 3.14 | -4.98 | 57.59 | -2.17 |
Total Operating Expenses | 2,455 | 2,255 | 1,327 | 895.85 | 941.14 | 877.55 |
Operating Income | 6,827 | 6,959 | -1,272 | -572.24 | -837.15 | -784.32 |
Interest Income | 456.09 | 374.42 | 240.26 | 54.12 | 133.27 | 41.21 |
Interest Expense | -339.78 | -332.8 | -51.5 | -190.74 | -268.16 | -15.78 |
Total Non-Operating Income (Expense) | 116.31 | 41.63 | 188.76 | -136.63 | -134.89 | 25.43 |
Pretax Income | 6,944 | 7,001 | -1,083 | -708.87 | -972.04 | -758.89 |
Provision for Income Taxes | -547.43 | -546.06 | 4.62 | 5.13 | 6.43 | 3.95 |
Net Income | 7,491 | 7,547 | -1,088 | -703.74 | -965.61 | -754.94 |
Earnings From Discontinued Operations | - | - | - | - | -236.53 | -263.21 |
Net Income to Common | 6,396 | 6,455 | -1,079 | -703.74 | -1,202 | -1,018 |
Shares Outstanding (Basic) | 71 | 71 | 66 | 57 | 46 | 43 |
Shares Outstanding (Diluted) | 72 | 72 | 66 | 57 | 46 | 43 |
Shares Change (YoY) | 4.80% | 7.70% | 17.40% | 22.49% | 7.77% | 11.73% |
EPS (Basic) | 90.44 | 91.56 | -16.24 | -12.44 | -26.02 | -23.75 |
EPS (Diluted) | 89.09 | 90.22 | -16.24 | -12.44 | -26.02 | -23.75 |
Free Cash Flow | 6,324 | 6,499 | -940.87 | -436.91 | -954.02 | -1,234 |
Free Cash Flow Growth | -2.69% | - | - | - | - | - |
Free Cash Flow Per Share | 88.08 | 90.83 | -14.16 | -7.72 | -20.65 | -28.79 |
Gross Margin | 100.00% | 99.99% | 87.44% | 94.41% | 100.00% | 89.89% |
Operating Margin | 73.88% | 75.52% | -2029.33% | -166.94% | -805.06% | -722.57% |
Profit Margin | 81.07% | 81.90% | -1735.60% | -205.30% | -928.60% | -695.50% |
FCF Margin | 68.44% | 70.52% | -1500.80% | -127.46% | -917.45% | -1136.94% |
EBITDA | 6,859 | 6,987 | -1,246 | -547.15 | -719.19 | -741.37 |
EBITDA Margin | 74.22% | 75.82% | -1988.10% | -159.62% | -691.62% | -683.00% |
EBIT | 6,827 | 6,959 | -1,272 | -572.24 | -837.15 | -784.32 |
EBIT Margin | 73.88% | 75.52% | -2029.33% | -166.94% | -805.06% | -722.57% |
Effective Tax Rate | -7.88% | -7.80% | -0.43% | -0.72% | -0.66% | -0.52% |